RMD and CSL Limited: 2 ASX shares to dig into
Rask Invest Research Team
December 4, 2023
The Resmed CDI (ASX:RMD) share price has decreased 20.1% since
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The Resmed CDI (ASX:RMD) share price has decreased 20.1% since
The CSL Limited (ASX:CSL) share price is down around 6.7%
The Resmed CDI (ASX:RMD) share price is down around 21.8%
The CSL Limited (ASX:CSL) share price has decreased 8.7% since
The Resmed CDI (ASX:RMD) share price has decreased 23.1% since
The CSL Limited (ASX:CSL) share price is down around 8.5%
Both Australia’s largest benchmarks weakened on Wednesday, despite news that
The Resmed CDI (ASX:RMD) share price is down around 25.0%
The CSL Limited (ASX:CSL) share price has decreased 8.2% since
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
